TLR4 and inflammatory bowel disease: In conclusion, BTL-1 showed an anti-inflammatory effect in LPS-induced IPEC-J2 inflammation and DSS-induced IBD mouse models via TLR4/NF-κB and MAPK signaling pathways, resulting in the inhibition of pro-inflammatory cytokines expression.